JP2018522579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522579A5 JP2018522579A5 JP2018512825A JP2018512825A JP2018522579A5 JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5 JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- supernatant
- cell culture
- level
- vitro cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021158571A JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164367P | 2015-05-20 | 2015-05-20 | |
| US62/164,367 | 2015-05-20 | ||
| US201662320032P | 2016-04-08 | 2016-04-08 | |
| US62/320,032 | 2016-04-08 | ||
| PCT/US2016/033187 WO2016187378A1 (en) | 2015-05-20 | 2016-05-19 | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Division JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522579A JP2018522579A (ja) | 2018-08-16 |
| JP2018522579A5 true JP2018522579A5 (enExample) | 2019-06-27 |
Family
ID=57320751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512825A Pending JP2018522579A (ja) | 2015-05-20 | 2016-05-19 | アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 |
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10548976B2 (enExample) |
| EP (2) | EP3298034A4 (enExample) |
| JP (2) | JP2018522579A (enExample) |
| CN (1) | CN108350057A (enExample) |
| CA (1) | CA2986432A1 (enExample) |
| HK (1) | HK1252174A1 (enExample) |
| MA (1) | MA42160A (enExample) |
| WO (1) | WO2016187378A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| TWI730949B (zh) | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CN119241685A (zh) | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| CN110099995A (zh) * | 2017-01-06 | 2019-08-06 | 奥林巴斯株式会社 | 细胞观察系统 |
| CN111801112A (zh) * | 2017-11-09 | 2020-10-20 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| WO2019217715A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP7388679B2 (ja) * | 2019-05-28 | 2023-11-29 | 学校法人 東洋大学 | 熱中症マーカー及びその利用 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3176735A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| EP4142769A4 (en) | 2020-04-28 | 2024-05-15 | Acceleron Pharma Inc. | ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION |
| PE20230783A1 (es) * | 2020-06-23 | 2023-05-11 | Acceleron Pharma Inc | Proteinas actrii para el tratamiento de la hipertension pulmonar |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| WO2022098877A1 (en) * | 2020-11-06 | 2022-05-12 | Acceleron Pharma Inc. | Formulations comprising actrii polypeptide variants |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000046349A1 (en) | 1999-02-04 | 2000-08-10 | Technion Research & Development Foundation Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| EP1824796A4 (en) | 2004-11-16 | 2010-02-17 | Avidia Res Inst | PROTEIN SKELETONS AND USES THEREOF |
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| WO2008076437A2 (en) | 2006-12-18 | 2008-06-26 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI626945B (zh) * | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ， インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| EP3290439B1 (en) | 2009-06-12 | 2020-09-02 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| CN102655872B (zh) | 2009-08-13 | 2016-01-20 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| JP6211767B2 (ja) | 2009-09-09 | 2017-10-11 | アクセルロン ファーマ， インコーポレイテッド | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| WO2011056896A1 (en) | 2009-11-03 | 2011-05-12 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| KR20140084211A (ko) * | 2011-10-17 | 2014-07-04 | 악셀레론 파마 인코포레이티드 | 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물 |
| CA2889286A1 (en) | 2012-10-24 | 2014-05-01 | Celgene Corporation | Methods for treating anemia |
| EP2912462B1 (en) | 2012-10-24 | 2019-08-07 | Celgene Corporation | Biomarker for use in treating anemia |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| BR112016024319B1 (pt) | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| TWI730949B (zh) | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP6976859B2 (ja) | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| CN116531490A (zh) | 2016-07-15 | 2023-08-04 | 阿塞勒隆制药公司 | 用于治疗肺高血压的组合物和方法 |
| HUE067225T2 (hu) | 2016-07-27 | 2024-10-28 | Acceleron Pharma Inc | Mielofibrózis kezelésére szolgáló készítmények |
| HUE068733T2 (hu) | 2017-06-14 | 2025-01-28 | Celgene Corp | Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére |
-
2016
- 2016-05-19 EP EP16797267.8A patent/EP3298034A4/en not_active Withdrawn
- 2016-05-19 WO PCT/US2016/033187 patent/WO2016187378A1/en not_active Ceased
- 2016-05-19 JP JP2018512825A patent/JP2018522579A/ja active Pending
- 2016-05-19 CN CN201680042691.9A patent/CN108350057A/zh active Pending
- 2016-05-19 HK HK18111575.0A patent/HK1252174A1/zh unknown
- 2016-05-19 CA CA2986432A patent/CA2986432A1/en active Pending
- 2016-05-19 MA MA042160A patent/MA42160A/fr unknown
- 2016-05-19 US US15/574,897 patent/US10548976B2/en not_active Expired - Fee Related
- 2016-05-19 EP EP22201847.5A patent/EP4190805A3/en not_active Withdrawn
-
2019
- 2019-12-11 US US16/711,039 patent/US20200101157A1/en not_active Abandoned
-
2021
- 2021-09-29 JP JP2021158571A patent/JP2022023072A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12351632B2 (en) | Anti-TCR antibody molecules and uses thereof | |
| Verdon et al. | Cellular and molecular mechanisms of CD8+ T cell differentiation, dysfunction and exhaustion | |
| Madonna et al. | The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis | |
| US10808009B2 (en) | Peptide conjugates | |
| ES2900233T3 (es) | Moléculas que se unen a CD70 y métodos de uso de las mismas | |
| Acharya et al. | Interleukin-17A promotes CD8+ T cell cytotoxicity to facilitate West Nile virus clearance | |
| Deckers et al. | Innate immune cells in asthma | |
| JP7289562B2 (ja) | 抗ｂｃｍａ単一ドメイン抗体及びその適用 | |
| US20230197187A1 (en) | Selective peptide antagonists | |
| JP2018184428A5 (enExample) | ||
| AU2016313107A1 (en) | Conditionally active chimeric antigen receptors for modified T-cells | |
| JP2020522254A (ja) | 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用 | |
| US11111288B2 (en) | Conditionally active chimeric antigen receptors for modified t-cells | |
| Paroli et al. | The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment | |
| KR20240004462A (ko) | Tcr에 결합하는 다기능성 분자 및 이의 용도 | |
| CN120943971A (zh) | 用于刺激自然杀伤细胞的组合物和方法 | |
| JP2020512284A5 (enExample) | ||
| JP2025534725A (ja) | Ｔｃｒに結合する多機能分子およびその使用 | |
| Gonzalez-Garcia et al. | Specific activation of T cells by an ACE2-based CAR-like receptor upon recognition of SARS-CoV-2 spike protein | |
| JP2021536256A (ja) | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 | |
| Ravichandran et al. | IL-17A expression in HIV-specific CD8 T cells is regulated by IL-4/IL-13 following HIV-1 prime-boost immunization | |
| Zhang et al. | Development of BCMA-targeted bispecific natural killer cell engagers for multiple myeloma treatment | |
| Steele et al. | The metabolic reprogramming of T cells controls airway remodeling in severe asthma | |
| WO2024259186A2 (en) | Cd74 car-t therapy and methods of use thereof | |
| JP2024538064A (ja) | ミクログリア活性化を抑制するための方法 |